Zamir Chen Stein, Dahan Dana Bardugo, Shoob Hanna
Jerusalem District Health Office, Ministry of health, Jerusalem, Israel; Braun School of Public Health and Community Medicine, The Hebrew University and Hadassah, Jerusalem, Israel.
Jerusalem District Health Office, Ministry of health, Jerusalem, Israel; Braun School of Public Health and Community Medicine, The Hebrew University and Hadassah, Jerusalem, Israel.
Vaccine. 2015 Apr 21;33(17):2073-8. doi: 10.1016/j.vaccine.2015.02.050. Epub 2015 Feb 27.
Pertussis is a contagious bacterial disease causing substantial health burden. Pertussis-related morbidity and mortality are highest in young infants. We investigated risk markers for pertussis and vaccination status in infants.
Reported pertussis cases under one year old during 1998-2011 in the Jerusalem district were matched to controls by birthdate and residence. Data sources included epidemiological investigations, health records and vaccination records (number and dates of DTP\DTaP doses scheduled at 2, 4, 6 months). Vaccine effectiveness was calculated by number of vaccine doses stratified by age group. Timeliness of vaccine doses was also evaluated.
The study population included 1268 infants under 1 year: 317 pertussis cases and 951 age-matched controls (mean age 3.95±3, median 2.9 months). Low birthweight (<2500g, 12.3% in cases vs. 6.3% in controls) and high birth order (4th and above) were found to be independent risk markers. Male gender and low socio-economic status were more frequent among cases. Some 40% of the cases (127/317) were hospitalized, most of them (111/127, 87.4%) were under 4 months (mean age 2.42±2.05, median 1.8 months). The distribution of the number of pertussis vaccine doses 0, 1, 2 and 3 differed considerably being 42.2%, 32.7%, 15.6%, 9.5% vs. 13.7%, 41.9%, 22.9%, 21.5% among cases and controls (≥2m), respectively. The overall vaccine effectiveness found was 72.9%, 76.1% and 84.4%, for the 1st, 2nd and 3rd doses of a pertussis vaccine. The infant's age at the first dose of pertussis vaccine was recorded with follow-up until age 18 months. Delay was more common among cases with a lower proportion vaccinated-78.9% at 18 months vs. 99% in controls.
Specific risk markers for pertussis in young infants were identified. Reported pertussis cases over age 2 months were significantly more likely to be unvaccinated and have delayed vaccinations. The vaccine effectiveness increased with the number of vaccine doses.
百日咳是一种传染性细菌性疾病,会造成巨大的健康负担。百日咳相关的发病率和死亡率在小婴儿中最高。我们调查了婴儿百日咳的风险标志物和疫苗接种状况。
将1998年至2011年耶路撒冷地区报告的1岁以下百日咳病例按出生日期和居住地与对照进行匹配。数据来源包括流行病学调查、健康记录和疫苗接种记录(2、4、6个月计划接种的百白破/无细胞百白破疫苗剂量及日期)。按年龄组分层,根据疫苗剂量计算疫苗效力。还评估了疫苗接种剂量的及时性。
研究人群包括1268名1岁以下婴儿:317例百日咳病例和951名年龄匹配的对照(平均年龄3.95±3岁,中位数2.9个月)。低出生体重(<2500g,病例组为12.3%,对照组为6.3%)和高出生顺序(第4胎及以上)被发现是独立的风险标志物。病例中男性和社会经济地位低的情况更常见。约40%的病例(127/317)住院,其中大多数(111/127,87.4%)年龄在4个月以下(平均年龄2.42±2.05岁,中位数1.8个月)。百日咳疫苗接种剂量为0、1、2和3剂的分布差异很大,病例组和对照组(≥2个月)分别为42.2%、32.7%、15.6%、9.5%和13.7%、41.9%、22.9%、21.5%。发现百日咳疫苗第1、2和3剂的总体疫苗效力分别为72.9%、76.1%和84.4%。记录了婴儿第一剂百日咳疫苗接种时的年龄,并随访至18个月。病例中延迟接种更常见,18个月时接种比例较低——病例组为78.9%,对照组为99%。
确定了小婴儿百日咳的特定风险标志物。报告的2个月以上百日咳病例未接种疫苗和延迟接种疫苗的可能性明显更高。疫苗效力随疫苗接种剂量的增加而提高。